143 related articles for article (PubMed ID: 36168243)
1. Relationship between Androgen Deprivation Therapy and Normal-Tension Glaucoma in Patients with Prostate Cancer: A Nationwide Cohort Study.
Ha JS; Lee HS; Park JY; Jeon J; Kim DK; Kim M; Hwang HS; Kim TH; Ahn HK; Cho KS
Yonsei Med J; 2022 Oct; 63(10):908-914. PubMed ID: 36168243
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation therapy may reduce the risk of primary open-angle glaucoma in patients with prostate cancer: a nationwide population-based cohort study.
Ahn HK; Lee HS; Park JY; Kim DK; Kim M; Hwang HS; Kim JW; Ha JS; Cho KS
Prostate Int; 2021 Dec; 9(4):197-202. PubMed ID: 35059357
[TBL] [Abstract][Full Text] [Related]
3. Androgen-deprivation therapy and the risk of newly developed fractures in patients with prostate cancer: a nationwide cohort study in Korea.
Kim DK; Lee HS; Park JY; Kim JW; Ahn HK; Ha JS; Cho KS
Sci Rep; 2021 May; 11(1):10057. PubMed ID: 33980958
[TBL] [Abstract][Full Text] [Related]
4. Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study.
Kim DK; Lee HS; Park JY; Kim JW; Ha JS; Kim JH; Yang WJ; Cho KS
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1217-1226. PubMed ID: 33000338
[TBL] [Abstract][Full Text] [Related]
5. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
6. Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population-based propensity score matching study.
Tae BS; Jeon BJ; Choi H; Bae JH; Park JY
Cancer Med; 2019 Aug; 8(9):4475-4483. PubMed ID: 31183968
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders.
Liu JM; Liu YP; Chuang HC; Wu CT; Su YL; Hsu RJ
PLoS One; 2020; 15(2):e0229263. PubMed ID: 32074125
[TBL] [Abstract][Full Text] [Related]
8. Androgen Deprivation Therapy in Patients with Prostate Cancer is Associated with the Risk of Subsequent Alzheimer's Disease but Not with Vascular Dementia.
Kim JW; Kim DK; Lee HS; Park JY; Ahn HK; Ha JS; Lee D; Cho KS
World J Mens Health; 2022 Jul; 40(3):481-489. PubMed ID: 34448373
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases.
Liu JM; Chen YT; Wu CT; Hsu WL; Hsu RJ
Prostate; 2022 May; 82(7):809-815. PubMed ID: 35226371
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases.
Liu JM; Yu CP; Chuang HC; Wu CT; Hsu RJ
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):475-482. PubMed ID: 30692587
[TBL] [Abstract][Full Text] [Related]
11. The use of androgen deprivation therapy for prostate cancer and its effect on the subsequent dry eye disease: a population-based cohort study.
Chien HW; Lin CW; Lee CY; Huang JY; Yang SF; Wang K
Int J Med Sci; 2022; 19(7):1103-1109. PubMed ID: 35919811
[TBL] [Abstract][Full Text] [Related]
12. Risk of colorectal adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer; a nationwide cohort study.
Shore R; Zhang J; Ye W; Stattin P; Lindblad M
Cancer Causes Control; 2023 Nov; 34(11):949-961. PubMed ID: 37341814
[TBL] [Abstract][Full Text] [Related]
13. Androgen Deprivation Therapy for Prostate Cancer Did Not Increase the Risk of Retinal Vascular Occlusion: A Population-Based Cohort Study.
Lin HL; Lee CY; Huang JY; Tseng PC; Yang SF
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206456
[TBL] [Abstract][Full Text] [Related]
14. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
[TBL] [Abstract][Full Text] [Related]
15. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy-related fracture risk in prostate cancer: an insurance claims database study in Japan.
Matsushima H; Taguchi T; Kodama S; Okubo N; Saito K; Jabłońska K; Fukumoto S; Matsumoto T
J Bone Miner Metab; 2024 Mar; 42(2):223-232. PubMed ID: 38493435
[TBL] [Abstract][Full Text] [Related]
17. Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study.
Kim JH; Bae GH; Jung J; Noh TI
World J Mens Health; 2024 Mar; ():. PubMed ID: 38606859
[TBL] [Abstract][Full Text] [Related]
18. Correlation of Androgen Deprivation Therapy with Cognitive Dysfunction in Patients with Prostate Cancer: A Nationwide Population-Based Study Using the National Health Insurance Service Database.
Tae BS; Jeon BJ; Shin SH; Choi H; Bae JH; Park JY
Cancer Res Treat; 2019 Apr; 51(2):593-602. PubMed ID: 30025445
[TBL] [Abstract][Full Text] [Related]
19. Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study.
Chiang IN; Huang CY; Pu YS; Chang CH; Muo CH; Chung CJ; Wang RY; Young TH
BMJ Open; 2017 Feb; 7(2):e012950. PubMed ID: 28246133
[TBL] [Abstract][Full Text] [Related]
20. New-onset diabetes after androgen-deprivation therapy for prostate cancer: A nationwide propensity score-matched four-year longitudinal cohort study.
Jhan JH; Yeh HC; Chang YH; Guu SJ; Wu WJ; Chou YH; Li CC
J Diabetes Complications; 2018 Jul; 32(7):688-692. PubMed ID: 29909141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
